An HDAC1, HDAC2, and HDAC3 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CXD101

Item No. 21159

Technical Information
Formal Name
N-(2-aminophenyl)-4-[1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-piperidinyl]-benzamide
CAS Number
934828-12-3
Synonyms
  • AZD 9468
  • HDAC-IN-4
  • Zabadinostat
Molecular Formula
C24H29N5O
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 10 mg/mlDMSO: 10 mg/mlDMSO:PBS (pH 7.2)(1:5): 0.16 mg/mlEthanol: 1 mg/ml
λmax
232, 298 nm
SMILES
NC1=CC=CC=C1NC(C2=CC=C(C3CCN(CC4=CN(C)N=C4C)CC3)C=C2)=O
InChi Code
InChI=1S/C24H29N5O/c1-17-21(15-28(2)27-17)16-29-13-11-19(12-14-29)18-7-9-20(10-8-18)24(30)26-23-6-4-3-5-22(23)25/h3-10,15,19H,11-14,16,25H2,1-2H3,(H,26,30)
InChi Key
JHDZMASHNBKTPS-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    CXD101 is a histone deacetylase 1 (HDAC1), HDAC2, and HDAC3 inhibitor (IC50s = 63, 570, and 550 nM, respectively).1 It increases acetylation of lysine 9 on histone H3 (H3K9Ac) in Colon-26 colon cancer cells when used at a concentration of 2.7 µM.2 CXD101 (50 mg/kg per day) decreases tumor volume, reduces tumor levels of macrophages, and increases tumor levels of Cd4+ and Cd8+ T cells without affecting body weight in a Colon-26 murine colon cancer model. It increases serum levels of IgG and IgM antibodies thirty days after administration in mice immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Eyre, T.A., Collins, G.P., Gupta, A., et alA phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer 125(1), 99-108 (2019).

    2. Blaszczak, W., Liu, G., Zhu, H., et alImmune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol. Oncol. 15(12), 3280-3298 (2021).

    3. Liu, G., Barczak, W., Lee, L.N., et alThe HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity. Commun. Biol. 6(1), 102 (2023).